Bortezomib
Bortezomib
About this item
Full title
Bortezomib
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Drug discovery, 2003-08, Vol.2 (8), p.611-612
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a blood cancer that affects two to three people per 100,000, in record time — four months — on the basis of positive outcomes in early-phase trials.
Alternative Titles
Full title
Bortezomib
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223586225
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223586225
Other Identifiers
ISSN
1474-1776
E-ISSN
1474-1784
DOI
10.1038/nrd1159
